Table of Contents Author Guidelines Submit a Manuscript
Prostate Cancer
Volume 2015, Article ID 285193, 10 pages
http://dx.doi.org/10.1155/2015/285193
Clinical Study

Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients

1Department of Oncology, Wayne State University and Karmanos Cancer Institute, Detroit, MI 48201, USA
2Department of Medicine, Wayne State University, Detroit, MI 48201, USA
3Roger Williams Medical Center, Providence, RI 02908, USA
4Department of Pathology, Roger Williams Medical Center, Providence, RI 02908, USA
5Department of Immunology and Microbiology, Wayne State University, Detroit, MI 48201, USA

Received 10 November 2014; Revised 9 January 2015; Accepted 15 January 2015

Academic Editor: Hendrik Van Poppel

Copyright © 2015 Ulka Vaishampayan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Ulka Vaishampayan, Archana Thakur, Ritesh Rathore, Nicola Kouttab, and Lawrence G. Lum, “Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients,” Prostate Cancer, vol. 2015, Article ID 285193, 10 pages, 2015. https://doi.org/10.1155/2015/285193.